Phenotypic expression is a prerequisite for malignant arrhythmic events and sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy

Europace

Volumn 18, Issue 7, 2016, Pages 1086-1094

  Zorzi, Alessandro ^a   Rigato, Ilaria ^a   Pilichou, Kalliopi ^a   Marra, Martina Perazzolo ^a   Migliore, Federico ^a   Mazzotti, Elisa ^a   Gregori, Dario ^a   Thiene, Gaetano ^a   Daliento, Luciano ^a   Iliceto, Sabino ^a   Rampazzo, Alessandra ^a   Basso, Cristina ^a   Bauce, Barbara ^a   Corrado, Domenico ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Arrhythmogenic right ventricular cardiomyopathy; Cardiomyopathy; Genetics; Implantable cardioverter defibrillator; Primary prevention; Sudden cardiac death; Ventricular arrhythmias

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; HEART FAILURE; HEART RIGHT VENTRICLE DYSPLASIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SUDDEN CARDIAC DEATH; ADVERSE EFFECTS; ARRHYTHMIAS, CARDIAC; COMPLICATION; DEATH, SUDDEN, CARDIAC; GENETICS; HETEROZYGOTE; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; MUTATION; PATHOLOGY; PRIMARY PREVENTION; SCAR; YOUNG ADULT;

DESMOGLEIN 2; DESMOPLAKIN; DSG2 PROTEIN, HUMAN; PKP2 PROTEIN, HUMAN; PLAKOPHILIN;

ADOLESCENT; ADULT; ARRHYTHMIAS, CARDIAC; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CICATRIX; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DESMOGLEIN 2; DESMOPLAKINS; FEMALE; HETEROZYGOTE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; PLAKOPHILINS; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84983670426     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv205     Document Type: Article

References (26)

1. Corrado D, Basso C, Pilichou K, Thiene G. Molecular biology and clinical management of arrhythmogenic right ventricular cardiomyopathy/dysplasia. Heart 2011; 97:530-9.
2. Basso C, Corrado D, Marcus F, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. Lancet 2009;373:1289-300.
3. Migliore F, Zorzi A, Silvano M, Rigato I, Basso C, Thiene G et al. Clinical management of arrhythmogenic right ventricular cardiomyopathy: an update. Curr Pharm Des 2010;16:2918-28.
4. Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2007;50:1813-21.
5. Patel HC, Calkins H. Arrhythmogenic right ventricular dysplasia. Curr Treat Options Cardiovasc Med 2010;12:598-613.
6. Cerrone M, Lin X, Zhang M, Agullo-Pascual E, Pfenniger A, Chkourko Gusky H et al. Missense mutations in plakophilin-2 cause sodium current deficit and associate with a brugada syndrome phenotype. Circulation 2014;129:1092-103.
7. Delmar M, Liang FX. Connexin43 and the regulation of intercalated disc function. Heart Rhythm 2012;9:835-8.
8. Gomes J, Finlay M, Ahmed AK, Ciaccio EJ, Asimaki A, Saffitz JE et al. Electrophysiological abnormalities precede overt structural changes in arrhythmogenic right ventricular cardiomyopathy due to mutations in desmoplakin-A combined murine and human study. Eur Heart J 2012;33:1942-53.
9. Kaplan SR, Gard JJ, Protonotarios N, Tsatsopoulou A, Spiliopoulou C, Anastasakis A et al. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm 2004;1:3-11.
10. Rizzo S, Lodder EM, Verkerk AO, Wolswinkel R, Beekman L, Pilichou K et al. Intercalated disc abnormalities, reduced Na(+) current density, and conduction slowing in desmoglein-2 mutant mice prior to cardiomyopathic changes. Cardiovasc Res 2012;95:409-18.
11. Sato PY, Musa H, Coombs W, Guerrero-Serna G, Patino GA, Taffet SM et al. Loss of plakophilin-2 expression leads to decreased sodium current and slower conduction velocity in cultured cardiac myocytes. Circ Res 2009;105:523-6.
12. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010;121:1533-41.
13. Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilichou K, Mazzotti E et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet 2013;6:533-42.
14. Blaker H. Confidence curves and improved exact confidence intervals for discrete distributions. Can J Stat 2000;28:783-9.
15. Fay MP. Two-sided exact tests and matching confidence intervals for discrete data. R J 2010;2:53-8.
16. Corrado D, Leoni L, Link MS, Della Bella P, Gaita F, Curnis A et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation 2003; 108:3084-91.
17. Bhonsale A, James CA, Tichnell C, Murray B, Gagarin D, Philips B et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol 2011;58:1485-96.
18. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 2010;122:1144-52.
19. Roguin A, Bomma CS, Nasir K, Tandri H, Tichnell C, James C et al. Implantable cardioverter-defibrillators in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2004;43:1843-52.
20. te Riele AS, Bhonsale A, James CA, Rastegar N, Murray B, Burt JR et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol 2013;62:1761-9.
21. Basso C, Bauce B, Corrado D, Thiene G. Pathophysiology of arrhythmogenic cardiomyopathy. Nat Rev Cardiol 2012;9:223-33.
22. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D et al. Leftdominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol 2008;52:2175-87.
23. Perazzolo Marra M, Leoni L, Bauce B, Corbetti F, Zorzi A, Migliore F et al. Imaging study of ventricular scar in arrhythmogenic right ventricular cardiomyopathy: comparison of 3D standard electroanatomical voltage mapping and contrast-enhanced cardiac magnetic resonance. Circ Arrhythm Electrophysiol 2012;5:91-100.
24. Bauce B, Basso C, Rampazzo A, Beffagna G, Daliento L, Frigo G et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J 2005;26:1666-75.
25. Sen-Chowdhry S, Syrris P, Ward D, Asimaki A, Sevdalis E, McKenna WJ. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation 2007;115:1710-20.
26. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace 2011;13:1077-109.